These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 19687233)
1. Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis. Drusano GL; Okusanya OO; Okusanya AO; van Scoy B; Brown DL; Fregeau C; Kulawy R; Kinzig M; Sörgel F; Heine HS; Louie A Antimicrob Agents Chemother; 2009 Nov; 53(11):4718-25. PubMed ID: 19687233 [TBL] [Abstract][Full Text] [Related]
2. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Louie A; VanScoy BD; Brown DL; Kulawy RW; Heine HS; Drusano GL Antimicrob Agents Chemother; 2012 Mar; 56(3):1229-39. PubMed ID: 22155821 [TBL] [Abstract][Full Text] [Related]
3. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A mBio; 2010 Aug; 1(3):. PubMed ID: 20802826 [TBL] [Abstract][Full Text] [Related]
4. Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations. Grohs P; Podglajen I; Gutmann L Antimicrob Agents Chemother; 2004 Aug; 48(8):3024-7. PubMed ID: 15273116 [TBL] [Abstract][Full Text] [Related]
5. Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument. Jorgensen JH; Crawford SA; McElmeel LM; Whitney CG J Clin Microbiol; 2004 Dec; 42(12):5928-30. PubMed ID: 15583344 [TBL] [Abstract][Full Text] [Related]
6. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002). Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476 [TBL] [Abstract][Full Text] [Related]
7. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070 [TBL] [Abstract][Full Text] [Related]
8. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004 [TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone resistance during 2000-2005: an observational study. Ryan RJ; Lindsell C; Sheehan P BMC Infect Dis; 2008 May; 8():71. PubMed ID: 18501015 [TBL] [Abstract][Full Text] [Related]
10. Interactions of antimicrobial peptide chrysophsin-3 with Bacillus anthracis in sporulated, germinated, and vegetative states. Pinzón-Arango PA; Nagarajan R; Camesano TA J Phys Chem B; 2013 May; 117(21):6364-72. PubMed ID: 23631815 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model. Odenholt I; Löwdin E; Gustafsson I; Cars O Antimicrob Agents Chemother; 2002 Jun; 46(6):2046-8. PubMed ID: 12019138 [TBL] [Abstract][Full Text] [Related]
12. Effect of single-walled carbon nanotubes on Bacillus anthracis cell growth, sporulation, and spore germination. Aferchich K; Lilly M; Yang L J Nanosci Nanotechnol; 2012 May; 12(5):3821-30. PubMed ID: 22852312 [TBL] [Abstract][Full Text] [Related]
13. Coordinated Assembly of the Bacillus anthracis Coat and Exosporium during Bacterial Spore Outer Layer Formation. Boone TJ; Mallozzi M; Nelson A; Thompson B; Khemmani M; Lehmann D; Dunkle A; Hoeprich P; Rasley A; Stewart G; Driks A mBio; 2018 Nov; 9(6):. PubMed ID: 30401771 [TBL] [Abstract][Full Text] [Related]
14. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin. Lismond A; Tulkens PM; Mingeot-Leclercq MP; Courvalin P; Van Bambeke F Antimicrob Agents Chemother; 2008 Sep; 52(9):3040-6. PubMed ID: 18573933 [TBL] [Abstract][Full Text] [Related]
15. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563 [TBL] [Abstract][Full Text] [Related]
16. Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice. Brook I; Germana A; Giraldo DE; Camp-Hyde TD; Bolduc DL; Foriska MA; Elliott TB; Thakar JH; Shoemaker MO; Jackson WE; Ledney GD J Antimicrob Chemother; 2005 Dec; 56(6):1074-80. PubMed ID: 16239289 [TBL] [Abstract][Full Text] [Related]
17. Germination and persistence of Bacillus anthracis and Bacillus thuringiensis in soil microcosms. Bishop AH J Appl Microbiol; 2014 Nov; 117(5):1274-82. PubMed ID: 25099131 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. Lee Y; Park Y; Kim MS; Yong D; Jeong SH; Lee K; Chong Y Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132 [TBL] [Abstract][Full Text] [Related]
19. Phenotypic changes in spores and vegetative cells of Bacillus anthracis associated with BenK. Heffron JD; Jenkins AL; Bozue JA; Kaatz LK; Cote CK; Welkos SL Microb Pathog; 2013 Apr; 57():41-51. PubMed ID: 23178382 [TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Somasundaram S; Paramasivan NC Chemotherapy; 2006; 52(4):190-5. PubMed ID: 16714850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]